Interferon Adjuvant to Radical Nephrectomy in Robson Stages II and III Renal Cell Carcinoma: A Multicentric Randomized Study

Abstract

Adjuvant rIFNalpha2b is not indicated after radical nephrectomy for renal cell carcinoma. The protective effect in the small group of pN2/pN3 patients requires further investigation.

Age at diagnosis is a determinant factor of renal cell carcinoma– specific survival in patients treated with nephrectomy

“…It is unlikely that adjuvant or salvage therapies have contributed to a significantly longer survival, because most historic regimens are associated with a dismal effect on survival. [15][16][17][18] Despite these limitations, our findings are novel and offer a new perspective about the effect of age on RCC prognosis. In addition, the sample size makes our findings highly generalizable.…”

Immunotherapy of Metastatic Renal Cell Cancer

“…The adjuvant use of IFN following metastasectomy has not been tested, but its use on an adjuvant schedule in high-risk patients who did not have metastatic cancer has been reported and appears not useful. 52 A trial of the addition of 13-cis-retinoic acid to an outpatient schedule of IFN-α was reported by Motzer et al 53 The combination arm had a 12% vs 6% (P=.14) overall response rate, 19% of patients in the combination arm were progression-free at 24 months compared with 10% in the second arm, and longer duration of responses were achieved (33 vs 22 months, P=.03). However, median survival was comparable (P=.26), and quality of life was poorer for the combination arm, especially during the first 8 weeks of treatment.…”

Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)

“…However, recent studies employing a-IFN-based therapy in the adjuvant setting for renal cell carcinoma patients also did not result in significant improvement regarding relapse-free survival and overall survival (Pizzocaro et al, 2001;Messing et al, 2003).…”

“…In studies of Pizzocaro et al (2001), an adjuvant treatment with IFN-alfa2b demonstrated a decrease in relapse rates in 26 patients with extensive nodal disease (pN2/pN3), but an increase in recurrence rates in node negative renal carcinoma patients.…”